National registry of endometrial cancer cases in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational program will create a centralized, systematic archive of epidemiological, clinical, surgical, pathological, and molecular (IHC and/or NGS) data for patients diagnosed with endometrial cancer at participating Italian reference centers. Data capture will include stage, grade, histotype, treatment details (including surgical approach), and follow-up outcomes to allow retrospective and future prospective analyses. The protocol emphasizes rigorous, continuous data recording modeled on registries like SEER to enable quality-control and longitudinal monitoring. Collected data will be used to describe population-level patterns, correlate molecular profiles with treatments and outcomes, and identify areas for improvement in national care pathways.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)
* age \> 18 years
* American Society of Anesthesiologists classification (ASA score) 1-3
* patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and/or NGS studies have been performed for the molecular profile of the carcinoma
* Signed informed consent

Exclusion Criteria:

* patients with missing information
* patients not treated in the participating centers for which only partial and fragmented information will be available
* molecular profile not known and\\or not recoverable and retrospectively analysable

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Francesco Fanfani — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Francesco Fanfani, MD
• Email: francesco.fanfani@policlinicogemelli.it
• Phone: +390630133421

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMTCuff vs standard TOF monitoring during gynecologic oncology surgery

  This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.

  Recruiting Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ankara · NCT07925463

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Personalized supervised exercise program for adults with breast or gynecologic cancer

  A small pilot study will test a supervised, personalized exercise program to see if it is safe, feasible, and acceptable for adults with a history of breast or gynecologic cancer.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07765927

• Cesium-131 brachytherapy to preserve organs in recurrent cervical or endometrial cancer

  This study tests whether implanting small cesium-131 seeds can provide targeted radiation to vaginal recurrences of cervical or endometrial cancer in patients who previously had pelvic radiation, with the goal of preserving organs.

  Recruiting University of Kentucky · Lexington, Kentucky · NCT07631572

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.